CA3189989A1 - Abiraterone prodrugs - Google Patents
Abiraterone prodrugsInfo
- Publication number
- CA3189989A1 CA3189989A1 CA3189989A CA3189989A CA3189989A1 CA 3189989 A1 CA3189989 A1 CA 3189989A1 CA 3189989 A CA3189989 A CA 3189989A CA 3189989 A CA3189989 A CA 3189989A CA 3189989 A1 CA3189989 A1 CA 3189989A1
- Authority
- CA
- Canada
- Prior art keywords
- abiraterone
- subject
- oil
- decanoate
- prostate cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073502P | 2020-09-02 | 2020-09-02 | |
| US63/073,502 | 2020-09-02 | ||
| PCT/US2021/048607 WO2022051330A1 (en) | 2020-09-02 | 2021-09-01 | Abiraterone prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3189989A1 true CA3189989A1 (en) | 2022-03-10 |
Family
ID=77951832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3189989A Pending CA3189989A1 (en) | 2020-09-02 | 2021-09-01 | Abiraterone prodrugs |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240050447A1 (https=) |
| EP (1) | EP4208171A1 (https=) |
| JP (1) | JP7850366B2 (https=) |
| CN (1) | CN116490165A (https=) |
| AU (1) | AU2021338271A1 (https=) |
| CA (1) | CA3189989A1 (https=) |
| IL (1) | IL300837A (https=) |
| MX (1) | MX2023002478A (https=) |
| WO (1) | WO2022051330A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10792292B2 (en) | 2019-03-06 | 2020-10-06 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| US11957696B2 (en) | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| WO2024107928A1 (en) | 2022-11-16 | 2024-05-23 | Propella Therapeutics, Inc. | Abiraterone decanoate composition and use in therapy |
| CN116287275B (zh) * | 2023-04-10 | 2024-04-05 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用 |
| WO2025240673A1 (en) * | 2024-05-15 | 2025-11-20 | Cardiff Oncology, Inc. | Cancer treatment using akt inhibitors and plk1 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20121788A1 (it) * | 2012-10-22 | 2014-04-23 | Olon Spa | Procedimento per la purificazione di abiraterone acetato |
| WO2014111815A2 (en) * | 2013-01-18 | 2014-07-24 | Cortendo Ab (Publ) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction |
| CN104017045B (zh) * | 2014-06-23 | 2016-01-13 | 广州艾格生物科技有限公司 | 甾体cyp17抑制剂的新型药物前体及其应用、制备方法 |
| US10722527B2 (en) * | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
| EP3394080B1 (en) * | 2015-12-23 | 2023-06-07 | The University Of British Columbia | Lipid-linked prodrugs |
| CN106977577A (zh) * | 2017-04-21 | 2017-07-25 | 湖南师范大学 | 两类阿比特龙衍生物的合成 |
| WO2020081999A1 (en) | 2018-10-18 | 2020-04-23 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| US10792292B2 (en) * | 2019-03-06 | 2020-10-06 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| US11957696B2 (en) * | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| JP2024533332A (ja) * | 2021-09-08 | 2024-09-12 | プロペラ セラピューティクス インコーポレイテッド | 経口アビラテロン製剤 |
| CA3243913A1 (en) * | 2022-03-01 | 2023-09-07 | Astellas Us Llc | Abiraterone prodrugs |
-
2021
- 2021-09-01 CN CN202180070124.5A patent/CN116490165A/zh active Pending
- 2021-09-01 CA CA3189989A patent/CA3189989A1/en active Pending
- 2021-09-01 JP JP2023514424A patent/JP7850366B2/ja active Active
- 2021-09-01 AU AU2021338271A patent/AU2021338271A1/en active Pending
- 2021-09-01 US US17/635,106 patent/US20240050447A1/en active Pending
- 2021-09-01 MX MX2023002478A patent/MX2023002478A/es unknown
- 2021-09-01 IL IL300837A patent/IL300837A/en unknown
- 2021-09-01 EP EP21778634.2A patent/EP4208171A1/en active Pending
- 2021-09-01 WO PCT/US2021/048607 patent/WO2022051330A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN116490165A (zh) | 2023-07-25 |
| EP4208171A1 (en) | 2023-07-12 |
| US20240050447A1 (en) | 2024-02-15 |
| MX2023002478A (es) | 2023-03-27 |
| JP2023539371A (ja) | 2023-09-13 |
| WO2022051330A1 (en) | 2022-03-10 |
| IL300837A (en) | 2023-04-01 |
| AU2021338271A1 (en) | 2023-03-30 |
| JP7850366B2 (ja) | 2026-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12138273B2 (en) | Abiraterone prodrugs | |
| US11957696B2 (en) | Abiraterone prodrugs | |
| CA3189989A1 (en) | Abiraterone prodrugs | |
| US20250025417A1 (en) | Oral abiraterone formulations | |
| US20250186463A1 (en) | Abiraterone decanoate prodrugs and use in therapy | |
| RU2822219C2 (ru) | Пролекарства абиратерона | |
| HK40103488A (en) | Abiraterone prodrugs | |
| HK40096900A (zh) | 阿比特龙前药 | |
| WO2024107928A1 (en) | Abiraterone decanoate composition and use in therapy | |
| HK40096901A (zh) | 阿比特龙前药 | |
| HK40130201A (zh) | 阿比特龙前药 | |
| HK40065545B (zh) | 阿比特龙前药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240823 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240823 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240823 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241119 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250317 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250822 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250908 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260217 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260325 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260325 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260331 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260331 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260331 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260331 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260331 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260331 |